Glenmark Pharmaceuticals has started a multi-country Phase 3 clinical trial for Envafolimab, a treatment for resectable Stage III Non-Small Cell Lung Cancer, with patient enrollment approved in India and ongoing applications in Russia, Brazil, and Mexico, as of September 5, 2025.